Novocure announced that former President Frank Leonard will take the helm as chief executive officer, effective December 1, 2025. Leonard has spent more than 15 years with the company, rising through the ranks to lead global business operations and drive the launch of its flagship Tumor Treating Fields (TTFields) therapy for glioblastoma.
The leadership change comes at a time when Novocure is grappling with persistent profitability pressures. The company has reported modest revenue growth, a negative earnings‑per‑share figure, and a high debt load that has kept cash flow negative. These financial headwinds have weighed on investor confidence and underscored the need for a CEO who can steer the firm toward sustainable profitability.
Leonard’s appointment is also tied to Novocure’s strategic pivot from a glioblastoma‑centric focus to a broader multi‑indication oncology platform. The company is advancing TTFields into non‑small cell lung cancer, pancreatic cancer, and other aggressive solid tumors, and is preparing for several regulatory reviews that could unlock new revenue streams.
Executive Chairman William Doyle praised Leonard’s long‑term stewardship, noting that he “has been instrumental in building the culture and business functions that have driven growth.” Leonard echoed that sentiment, saying the patient remains at the center of the company’s mission and that he is “honored to lead Novocure as we launch products in new indications and complete clinical trials.”
Investors have responded cautiously, citing the company’s ongoing profitability challenges, high leverage, and negative cash flow. The appointment signals a commitment to continuity and a focus on turning the financial picture around while pursuing the expanded pipeline.
With Leonard at the helm, Novocure aims to combine disciplined cost management with aggressive pipeline development, hoping to restore profitability and deliver value to patients and stakeholders over the long term.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.